Hiroshi Date

Has grant

Duke University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

自然免疫の活性化が誘因となる移植肺機能不全の抑制

Open Date: 2020-04-01

Close Date: 2023-03-31

Grant: Close

献体による効果的医療技術教育システムの普及促進に関する研究

Open Date: 2019-04-01

Close Date: 2020-03-31

Grant: Close

ドナーグラフト内の白血球を標的とした肺移植における新規治療法の開発

Open Date: 2019-04-01

Close Date: 2022-03-31

Grant: Close

肺移植における体外肺灌流保存(EVLP)を用いたマージナルドナー肺の治療

Open Date: 2018-04-01

Close Date: 2020-03-31

Grant: Close

Development of selective immunosuppressive therapy preserving natural immunity for treating chronic rejection after lung transplantation

Open Date: 2018-04-01

Close Date: 2021-03-31

Articles (7)

Background The vascular division sequence in video-assisted thoracic surgery (VATS) lung resection is usually determined by the handling difficulty due to the limited surgical view through the scope. However, upfront pulmonary vein division is theoretically desirable to avoid tumor cells spreading by surgical manipulation. Epithelial–mesenchymal transition (EMT) is associated with poor prognosis and an increased number of circulating tumor cells. The purpose of this study is to evaluate the effect of vascular division sequence and EMT on postoperative recurrence. Methods We retrospectively investigated tissue microarrays of 282 lung adenocarcinomas surgically resected between 2001 and 2007. We excluded the cases with segmentectomy, wedge resection, dissemination, insufficient material for staining, or lack of medical records. The effect of vascular division sequence and clinicopathologic factors on recurrence was evaluated in 195 cases. Results The upfront pulmonary vein division (V-first) was performed in 60 patients, and the upfront pulmonary artery division (A-first) was performed in 135 patients. The recurrence was observed in 67 patients (13 in V-first and 54 in A-first). Epithelial–mesenchymal transition activation was observed in 104 patients. Multivariable analysis with 195 patients revealed that lymph node metastasis and pleural invasion were risk factors for the recurrence. The stratified multivariable analysis showed that vascular division sequence (A-first) was a risk factor only in the EMT-negative group (91 patients). In the EMT-negative subset, the 5-year relapse-free survival rate was significantly lower in the A-first group than the V-first group (72.6% vs. 92.2%, p = 0.0136). Conclusions The upfront pulmonary artery division might be a risk factor in patients without EMT activation.

Year:

2024

Glycolysis and mitochondrial fatty acid oxidation (FAO) regulate CD8+ T cell differentiation fate. However, how glycolysis and FAO balance are associated with T-cell exhaustion remains unknown. PD-1 signal inhibits glycolysis and enhances FAO. We find that CD8+ T cells in the tumors adhered to glycolysis with attenuated FAO despite high PD-1 expression, which was defined as “metabolic exhaustion.” Active aldehydes, final products of lipid peroxidation, accumulate in CD8+ T cells in proportion to their exhaustion depth in mouse and human tumor tissues. Active aldehydes strongly promote glycolysis and inhibit the FAO activity in T cells. Mice deficient for an FAO enzyme, specifically in T cells, generate more active aldehydes, enhancing T-cell exhaustion and attenuating anti-tumor immunity. Super-resolution microscopy analysis reveals that active aldehydes are primarily generated from mitochondria in the exhausted T cells, which is associated with mitochondrial damage. Inhibitors of lipid peroxidation or active aldehydes enhanced the anti-tumor effect of the PD-1 blockade therapy by rectifying metabolic exhaustion. Therefore, active aldehydes resulting from FAO impairment cause a vicious cycle of metabolic imbalance that leads to T cell exhaustion.

Year:

2024

With the emergence of lung cancer screening programmes and newly detected localised and multifocal disease, novel treatment compounds and multimodal treatment approaches, the treatment landscape of non-small cell lung cancer is becoming increasingly complex. In parallel, in-depth molecular analyses and clonality studies are revealing more information about tumorigenesis, potential therapeutical targets and the origin of lesions. All can play an important role in cases with multifocal disease, oligoprogression and oligorecurrence. In multifocal disease, it is essential to understand the relatedness of separate lesions for treatment decisions, because this information distinguishes separate early-stage tumours from locally advanced or metastatic cancer. Clonality studies suggest that a majority of same-histology lesions represent multiple primary tumours. With the current standard of systemic treatment, oligoprogression after an initial treatment response is a common scenario. In this state of induced oligoprogressive disease, local ablative therapy by either surgery or radiotherapy is becoming increasingly important. Another scenario involves the emergence of a limited number of metastases after radical treatment of the primary tumour, referred to as oligorecurrence, for which the use of local ablative therapy holds promise in improving survival. Our review addresses these complex situations in lung cancer by discussing current evidence, knowledge gaps and treatment recommendations.

Year:

2024

EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo . Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

Year:

2024

The management of malignant melanoma with pulmonary metastases is controversial and occasionally requires multimodality management, including pulmonary metastasectomy after immune checkpoint inhibitors (ICIs). However, limited data are available on these patients. We described a case series of three consecutive patients who underwent pulmonary metastasectomy after ICIs for malignant melanoma and discussed the important characteristics of these patients. After pulmonary metastasectomy, none of the patients had recurrent pulmonary metastases, although extrapulmonary metastases were developed. Our case series suggests that pulmonary metastasectomy after ICIs may control pulmonary metastases in carefully selected patients with malignant melanoma.

Year:

2024

OBJECTIVES Lung retransplantation has been performed as a treatment option mainly for chronic lung allograft dysfunction; however, the outcomes of lung retransplantation have been reported to be worse than those of primary lung transplantation. Because of the scarcity of deceased donors in our country, our lung transplant experience includes both living and deceased donors. Therefore, we have experienced lung retransplantation cases with various combinations of living and deceased donors. The aim of this study was to explore technical pitfalls and outcomes of lung retransplantation in this unique environment. METHODS We performed 311 lung transplantation procedures between April 2002 and October 2022. Eight lung retransplantation cases (2.6%) were analysed retrospectively. RESULTS At lung retransplantation, the age of the recipient patients ranged from 11 to 61 years (median, 33 years). The combinations of donor sources (primary lung transplantation/lung retransplantation) were as follows: 2 living/living, 2 deceased/living, 3 living/deceased and 1 deceased/deceased. Seven of 8 patients received lung retransplantation for chronic lung allograft dysfunction. Hospital death occurred in 2 patients (25.0%). The 1-, 3- and 5-year survival rates after lung retransplantation (n = 8) were 75.0%, 75.0% and 75.0%, respectively, while those after primary lung transplantation (n = 303) were 92.8%, 83.4% and 76.4%, respectively (P = 0.162). CONCLUSIONS Lung retransplantation with various combinations of living and deceased donors is a technically difficult but feasible procedure with acceptable outcomes.

Year:

2024

Background In interstitial pneumonia (IP)-associated lung cancer, immune checkpoint inhibitor pneumonitis (ICIP) is common with immune checkpoint inhibitor (ICI) treatment. The purpose of the present study was to clarify the safety and efficacy of ICI treatment for patients with lung cancer with IP. Methods This multicentre retrospective observational study was conducted from June 2016 to December 2020 in patients with primary lung cancer with IP who received ICI treatment. Results A total of 200 patients (median age 70 years; male/female, 176/24) were enrolled from 27 institutions. ICIP occurred in 61 patients (30.5%), pneumonitis grades 3–5 in 32 patients (15.5%) and death in nine patients (4.5%). The common computed tomography pattern of ICIP was organising pneumonia in 29 patients (47.5%). Subsequently, diffuse alveolar damage (DAD) pattern was observed in 19 patients (31.1%) who had a significantly worse prognosis than those with a non-DAD pattern (median progression-free survival (PFS) 115 days versus 226 days, p=0.042; median overall survival (OS) 334 days versus 1316 days, p<0.001). Immune-related adverse events (irAEs) occurred in approximately 50% of patients. Patients with irAEs (n=100) had a better prognosis than those without irAEs (n=100) (median PFS 200 days versus 77 days, p<0.001; median OS 597 days versus 390 days p=0.0074). The objective response rate and disease control rate were 41.3% and 68.5%, respectively. Conclusions Although ICI treatment was effective for patients with lung cancer with IP, ICIP developed in approximately 30% of patients. Patients with irAEs had a significantly better PFS and OS than those without irAEs.

Year:

2024

Collaborators (16)

Takashi Kobayashi

教授 / Professor

Kyoto University

JAPAN
View details

Satona Tanaka

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Tomoko Funazo

Kyoto University Hospital

JAPAN
View details

Daisuke Nakajima

講師 / Senior Lecturer/ Junior Associate Professor

Kyoto University

JAPAN
View details

Takashi Nomizo

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Akihiko Yoshizawa

Kyoto University Hospital

JAPAN
View details

hironori yoshida

Kyoto University Hospital

JAPAN
View details

Yasunari Miyazaki

-

JAPAN
View details

Hiroaki Ozasa

助教 / Assistant Professor

Kyoto University

JAPAN
View details

Kazuma Kishi

-

JAPAN
View details

Takahiro Tsuji

Fred Hutch Cancer Center

UNITED STATES
View details

Kazutaka Hosoya

Medical Staff

Kyoto University Hospital

JAPAN
View details

Toyohiro Hirai

Kyoto University

JAPAN
View details

Toshi Menju

Associate Professor

Kyoto University

JAPAN
View details

Tasuku Honjo

Deputy Director-General/Distinguished Professor

Kyoto University

JAPAN
View details

Yojiro Yutaka

Kyoto University

JAPAN
View details